Pioneering, proven pain treatment for knee OA
Arthrosamid® — The first and only synovial implant treatment administered via a single injectable for long-lasting pain relief.
UKpeople worldwide were living with osteoarthritis in 2019; an increase of 113% since 1990.
Despite osteoarthritis (OA) being the most common type of arthritis and the fastest-growing cause of disability worldwide, the treatment area has seen minimal progression in the last 20 years. With so little known about exactly what causes knee OA, a permanent cure has yet to be discovered.
Arthrosamid® is a non-biodegradable injectable polyacrylamide hydrogel (2.5% iPAAG) implant that delivers long-lasting pain relief — improving the quality of life for patients with knee OA.
Arthrosamid® is a first-in-class synovial implant delivered as a single, minimally invasive out-patient procedure performed under local anaesthesia, with ultrasound guidance.
Researched for more than two decades, Arthrosamid® has been proven to maintain a statistically significant reduction in pain in patients with knee OA 5 years after treatment.
A single, minimally invasive, long-lasting knee OA treatment, Arthrosamid® has demonstrated an improvement in quality of life with patients in clinical trials reporting a reduction in pain by Week 4 — and lasting over 5 years.
WOMAC pain subscale change from baseline across studies.
We are delighted to introduce our patient rehabilitation programme. Click on the link below to see the videos.